Statins as early therapy to mitigate COVID-19 (SARS-CoV-2)-associated ARDS and cytokine storm syndrome – time is of the essence
Narci Teoh, Geoff Farrell
Abstract
While most coronavirus disease 2019 (COVID-19) infections run a benign course with recovery, the inexorable rise in case fatalities in several countries is grim testimony to the lack of effective therapies to arrest the course of severe infections. Recent observations of Mehta et al. This leads us to propose an early, safe, and widely available pharmacological intervention that could be used pre-emptively to avert fatal outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients.
Topics & Concepts
Cytokine stormARDSMedicineCoronavirus disease 2019 (COVID-19)CoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PandemicCytokine release syndromeBetacoronavirus2019-20 coronavirus outbreakIntensive care medicineImmunologyVirologyDiseaseInfectious disease (medical specialty)LungInternal medicineOutbreakCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19